IAPSM’s Position Paper on the Human Papilloma Virus (HPV) Vaccine for Adult Immunization in India

Cervical cancer ranks as the second most common cancer in women in India, primarily caused by persistent infection with the human papillomavirus (HPV). Given its long latent period, secondary prevention through screening and early detection is essential. However, fear and stigma associated with canc...

Full description

Saved in:
Bibliographic Details
Main Authors: Ranjitha S. Shetty, Anuradha Nadda, Muralidhar Tambe, Abhishek Raut, Kapil Goel, Chythra R. Rao, Aprajita Mehta, Pankaj Bhardwaj, Madhu Gupta, Veena G Kamath
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2024-12-01
Series:Indian Journal of Community Medicine
Subjects:
Online Access:https://journals.lww.com/10.4103/ijcm.ijcm_738_24
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841556849884659712
author Ranjitha S. Shetty
Anuradha Nadda
Muralidhar Tambe
Abhishek Raut
Kapil Goel
Chythra R. Rao
Aprajita Mehta
Pankaj Bhardwaj
Madhu Gupta
Veena G Kamath
author_facet Ranjitha S. Shetty
Anuradha Nadda
Muralidhar Tambe
Abhishek Raut
Kapil Goel
Chythra R. Rao
Aprajita Mehta
Pankaj Bhardwaj
Madhu Gupta
Veena G Kamath
author_sort Ranjitha S. Shetty
collection DOAJ
description Cervical cancer ranks as the second most common cancer in women in India, primarily caused by persistent infection with the human papillomavirus (HPV). Given its long latent period, secondary prevention through screening and early detection is essential. However, fear and stigma associated with cancers and the costs involved in disease management are the prominent barriers to its uptake. HPV vaccination is one of the vital components of the World Health Organization’s (WHO) Global Strategy to speed up the elimination of cervical cancer as a public health problem. In India, four prophylactic HPV vaccines are currently available. These vaccines are non-infective and highly immunogenic, safe, and effective when administered before HPV exposure. According to WHO recommendations, the primary target group for HPV vaccination consists of girls between the ages of 9 and 14 years. Further, studies have confirmed that both single-dose and two-dose schedules of the HPV vaccine offer comparable efficacy and protection. HPV vaccines are administered intramuscularly in the deltoid region, with 0.5 ml as the standard dose. These vaccines may cause local reactions, as well as mild systemic reactions, such as headache and myalgia, but they are transient. Implementing catch-up vaccination for adolescent girls aged between 9 and 14 years at the time of HPV vaccine introduction would be a cost-effective and sustainable strategy. This would serve as a crucial component of public health efforts to manage HPV infections and eliminate cervical cancer in India.
format Article
id doaj-art-2cf1056ba75049d4949fdac371deb9c8
institution Kabale University
issn 0970-0218
1998-3581
language English
publishDate 2024-12-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Indian Journal of Community Medicine
spelling doaj-art-2cf1056ba75049d4949fdac371deb9c82025-01-07T06:06:04ZengWolters Kluwer Medknow PublicationsIndian Journal of Community Medicine0970-02181998-35812024-12-0149Suppl 2S125S13110.4103/ijcm.ijcm_738_24IAPSM’s Position Paper on the Human Papilloma Virus (HPV) Vaccine for Adult Immunization in IndiaRanjitha S. ShettyAnuradha NaddaMuralidhar TambeAbhishek RautKapil GoelChythra R. RaoAprajita MehtaPankaj BhardwajMadhu GuptaVeena G KamathCervical cancer ranks as the second most common cancer in women in India, primarily caused by persistent infection with the human papillomavirus (HPV). Given its long latent period, secondary prevention through screening and early detection is essential. However, fear and stigma associated with cancers and the costs involved in disease management are the prominent barriers to its uptake. HPV vaccination is one of the vital components of the World Health Organization’s (WHO) Global Strategy to speed up the elimination of cervical cancer as a public health problem. In India, four prophylactic HPV vaccines are currently available. These vaccines are non-infective and highly immunogenic, safe, and effective when administered before HPV exposure. According to WHO recommendations, the primary target group for HPV vaccination consists of girls between the ages of 9 and 14 years. Further, studies have confirmed that both single-dose and two-dose schedules of the HPV vaccine offer comparable efficacy and protection. HPV vaccines are administered intramuscularly in the deltoid region, with 0.5 ml as the standard dose. These vaccines may cause local reactions, as well as mild systemic reactions, such as headache and myalgia, but they are transient. Implementing catch-up vaccination for adolescent girls aged between 9 and 14 years at the time of HPV vaccine introduction would be a cost-effective and sustainable strategy. This would serve as a crucial component of public health efforts to manage HPV infections and eliminate cervical cancer in India.https://journals.lww.com/10.4103/ijcm.ijcm_738_24cervical cancerhpvimmunogenicityvaccinevirus-like-particle
spellingShingle Ranjitha S. Shetty
Anuradha Nadda
Muralidhar Tambe
Abhishek Raut
Kapil Goel
Chythra R. Rao
Aprajita Mehta
Pankaj Bhardwaj
Madhu Gupta
Veena G Kamath
IAPSM’s Position Paper on the Human Papilloma Virus (HPV) Vaccine for Adult Immunization in India
Indian Journal of Community Medicine
cervical cancer
hpv
immunogenicity
vaccine
virus-like-particle
title IAPSM’s Position Paper on the Human Papilloma Virus (HPV) Vaccine for Adult Immunization in India
title_full IAPSM’s Position Paper on the Human Papilloma Virus (HPV) Vaccine for Adult Immunization in India
title_fullStr IAPSM’s Position Paper on the Human Papilloma Virus (HPV) Vaccine for Adult Immunization in India
title_full_unstemmed IAPSM’s Position Paper on the Human Papilloma Virus (HPV) Vaccine for Adult Immunization in India
title_short IAPSM’s Position Paper on the Human Papilloma Virus (HPV) Vaccine for Adult Immunization in India
title_sort iapsm s position paper on the human papilloma virus hpv vaccine for adult immunization in india
topic cervical cancer
hpv
immunogenicity
vaccine
virus-like-particle
url https://journals.lww.com/10.4103/ijcm.ijcm_738_24
work_keys_str_mv AT ranjithasshetty iapsmspositionpaperonthehumanpapillomavirushpvvaccineforadultimmunizationinindia
AT anuradhanadda iapsmspositionpaperonthehumanpapillomavirushpvvaccineforadultimmunizationinindia
AT muralidhartambe iapsmspositionpaperonthehumanpapillomavirushpvvaccineforadultimmunizationinindia
AT abhishekraut iapsmspositionpaperonthehumanpapillomavirushpvvaccineforadultimmunizationinindia
AT kapilgoel iapsmspositionpaperonthehumanpapillomavirushpvvaccineforadultimmunizationinindia
AT chythrarrao iapsmspositionpaperonthehumanpapillomavirushpvvaccineforadultimmunizationinindia
AT aprajitamehta iapsmspositionpaperonthehumanpapillomavirushpvvaccineforadultimmunizationinindia
AT pankajbhardwaj iapsmspositionpaperonthehumanpapillomavirushpvvaccineforadultimmunizationinindia
AT madhugupta iapsmspositionpaperonthehumanpapillomavirushpvvaccineforadultimmunizationinindia
AT veenagkamath iapsmspositionpaperonthehumanpapillomavirushpvvaccineforadultimmunizationinindia